{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:27:10Z","timestamp":1762957630132,"version":"build-2065373602"},"reference-count":94,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: In this ongoing, multicenter, global cohort observational study, phenotypes of headaches after COVID-19 vaccination were directly compared between different vaccines. Methods: Phenotypes of postvaccinal headache were recorded in 18,544 participants. The study was launched immediately after the start of the global COVID-19 vaccination campaign on 12 January 2021 and continued until 1 August 2023. Specific aspects of headaches and related variables were collected via an online questionnaire. The clinical headache characteristics of patients vaccinated with the Comirnaty (BioNTech), Jcovden (Johnson &amp; Johnson), Sputnik V (Gamelaya), Covilo (Sinopharm), Spikevax (Moderna), Vaxzevria (AstraZeneca), and Convidecia (CanSino Biologics) vaccines were investigated. Results: Across all vaccines, the median and mean latency of headache onset after vaccine administration were 12 h and 23.3 h, respectively. The median and mean headache duration were 12 h and 23.3 h, respectively. When the nonreplicating viral vector vaccine Sputnik V was used, headaches occurred the fastest, with a latency of 17 h. The latencies for the Vaxzevria and Convidecia nonreplicating viral vector vaccines were 14.9 h and 19.1 h, respectively. The Covilo inactivated whole-virus vaccine had a latency of 20.5 h. The latencies of the mRNA-based Comirnaty and Spikevax vaccines were 26.0 h and 22.02 h, respectively. Analysis of variance revealed no significant differences in the mean duration of postvaccinal headache for the vaccines tested. Compared with the Comirnaty, Covilo, and Vaxzevria vaccines, the Spikevax vaccine induced significantly greater headache intensities. Vaxzevria was associated with a significantly higher frequency of concomitant symptoms than the other vaccines. Conclusions: The phenotype of postvaccinal headache can vary significantly between vaccines. These results have clinical implications for differentiating between postvaccinal headache and other primary and secondary headaches. This knowledge is clinically relevant in differentiating life-threatening vaccination complications, such as thrombotic syndromes, which are also associated with headaches. Based on these results, new diagnostic criteria for postvaccinal headaches can be developed.<\/jats:p>","DOI":"10.3390\/vaccines13020113","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T04:54:31Z","timestamp":1737608071000},"page":"113","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used"],"prefix":"10.3390","volume":"13","author":[{"given":"Carl Hartmut","family":"G\u00f6bel","sequence":"first","affiliation":[{"name":"Kiel Migraine and Headache Centre, 24149 Kiel, Germany"},{"name":"Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Heinze","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, 24149 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Heinze-Kuhn","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, 24149 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Karstedt","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, 24149 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mascha","family":"Morscheck","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, 24149 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-1811","authenticated-orcid":false,"given":"Lilian","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, 24149 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cirkel","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, 24149 Kiel, Germany"},{"name":"Department of Neurology, University Hospital Schleswig-Holstein, Campus L\u00fcbeck, 23562 L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1107-190X","authenticated-orcid":false,"given":"Qutyaba","family":"Hamid","sequence":"additional","affiliation":[{"name":"Sharjah Institute of Medical Research, University of Sharjah, Sharjah 26666, United Arab Emirates"},{"name":"Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 26666, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabih","family":"Halwani","sequence":"additional","affiliation":[{"name":"Sharjah Institute of Medical Research, University of Sharjah, Sharjah 26666, United Arab Emirates"},{"name":"Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 26666, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4389-9322","authenticated-orcid":false,"given":"Mohamad-Hani","family":"Temsah","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud University, Riyadh 12373, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0919-0237","authenticated-orcid":false,"given":"Malte","family":"Ziemann","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, Campus L\u00fcbeck, 23562 L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"G\u00f6rg","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, Campus L\u00fcbeck, 23562 L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"M\u00fcnte","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Schleswig-Holstein, Campus L\u00fcbeck, 23562 L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2163-112X","authenticated-orcid":false,"given":"Hartmut","family":"G\u00f6bel","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Centre, 24149 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijid.2020.02.052","article-title":"Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak","volume":"93","author":"Petersen","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ukwishaka, J., Ndayishimiye, Y., Destine, E., Danwang, C., and Kirakoya-Samadoulougou, F. (2023). Global prevalence of coronavirus disease 2019 reinfection: A systematic review and meta-analysis. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-15626-7"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1605421","DOI":"10.3389\/ijph.2023.1605421","article-title":"The COVID-19 Pandemic and Health and Care Workers: Findings From a Systematic Review and Meta-Analysis (2020\u20132021)","volume":"68","author":"Gholami","year":"2023","journal-title":"Int. J. Public Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000530536","article-title":"Prevalence and Mortality Risk of Neurological Disorders during the COVID-19 Pandemic: An Umbrella Review of the Current Evidence","volume":"57","author":"Park","year":"2023","journal-title":"Neuroepidemiology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gao, P., Liu, J., and Liu, M. (2022). Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph191912422"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rosa, S., da Silva, A.K.A., dos Santos, C.R., Silva, M.d.S., Perillo, A.L.P., Mendon\u00e7a, A.F., Rosa, M.F.F., Sampaio, T.L., Carneiro, M.L.B., and Rocha, J.C.T. (2022). Effects of vaccine registration on disease prophylaxis: A systematic review. Biomed. Eng. Online, 21.","DOI":"10.1186\/s12938-022-01053-z"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00103-022-03600-4","article-title":"Overview of COVID-19 vaccines licensed in the EU-from technology via clinical trial to registration","volume":"65","author":"Hildt","year":"2022","journal-title":"Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz"},{"key":"ref_9","first-page":"e16635","article-title":"Vaccine Development Throughout History","volume":"13","author":"Saleh","year":"2021","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tan, S.Y., Oka, P., and Tan, N.C. (2023). Intention to Vaccinate against COVID-19 in Adolescents: A Systematic Review. Vaccines, 11.","DOI":"10.3390\/vaccines11081393"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ribeiro, T.B., Roque, F., Ida, F., Pl\u00e1cido, A.I., Vu, M., Hern\u00e1ndez-Mu\u00f1oz, J.J., and Herdeiro, M.T. (2022). Early Real-World Data to Assess Benefits and Risks of COVID-19 Vaccines: A Systematic Review of Methods. Vaccines, 10.","DOI":"10.3390\/vaccines10111896"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wallace, M., Collins, J.P., Moline, H., Plumb, I.D., Godfrey, M., Morgan, R.L., Campos-Outcalt, D., Oliver, S.E., Dooling, K., and Gargano, J.W. (2022). Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0278624"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tian, Y., Chen, L., and Shi, Y. (2022). Safety, Efficacy, and Immunogenicity of Varying Types of COVID-19 Vaccines in Children Younger Than 18 Years: An Update of Systematic Review and Meta-Analysis. Vaccines, 11.","DOI":"10.3390\/vaccines11010087"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1865774","DOI":"10.1080\/21645515.2020.1865774","article-title":"Coronavirus (SARS-CoV-2): A systematic review for potential vaccines","volume":"18","author":"Bhatta","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2027160","DOI":"10.1080\/21645515.2022.2027160","article-title":"The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: A systematic review","volume":"18","author":"Mohammed","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jiph.2023.01.020","article-title":"Implications for COVID-19 vaccine uptake: A systematic review","volume":"16","author":"Adu","year":"2023","journal-title":"J. Infect. Public Health"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/s41467-023-37176-7","article-title":"Predicting vaccine effectiveness against severe COVID-19 over time and against variants: A meta-analysis","volume":"14","author":"Cromer","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2352-4642(23)00078-0","article-title":"Safety and effectiveness of vaccines against COVID-19 in children aged 5\u201311 years: A systematic review and meta-analysis","volume":"7","author":"Piechotta","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/jebm.12525","article-title":"Cost-effectiveness of COVID-19 vaccination: A systematic review","volume":"16","author":"Fu","year":"2023","journal-title":"J. Evid.-Based Med."},{"key":"ref_20","first-page":"1663","article-title":"COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e28623","DOI":"10.1002\/jmv.28623","article-title":"Effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis","volume":"95","author":"Zhang","year":"2023","journal-title":"J. Med Virol."},{"key":"ref_22","unstructured":"Basta NE and Moodie EMM on behalf of the VIPER (Vaccines Infectious disease Prevention and Epidemiology Research) Group COVID-19 Vaccine Development and Approvals Tracker Team (2023, August 29). COVID-19 Vaccine Development and Approvals Tracker. Available online: https:\/\/covid19.trackvaccines.org\/site-credits\/."},{"key":"ref_23","unstructured":"World Health Organization (2023, August 29). COVID-19 Vaccine Tracker and Landscape. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.vaccine.2023.03.056","article-title":"Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes","volume":"41","author":"Hu","year":"2023","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2010.10.005","article-title":"Shoulder injury related to vaccine administration (SIRVA)","volume":"28","author":"Atanasoff","year":"2010","journal-title":"Vaccine"},{"key":"ref_26","first-page":"100183","article-title":"Shoulder injury related to vaccine administration (SIRVA): What do we know about its incidence and impact?","volume":"8","author":"Mackenzie","year":"2022","journal-title":"Explor. Res. Clin. Soc. Pharm."},{"key":"ref_27","unstructured":"Robert Koch Institut (2023, August 29). Informationsmaterialien zum Impfen. Available online: https:\/\/www.rki.de\/DE\/Content\/Infekt\/Impfen\/Materialien\/materialien_fremdsprachig_node.html."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s10194-022-01400-4","article-title":"Headache onset after vaccination against SARS-CoV-2: A systematic literature review and meta-analysis","volume":"23","author":"Castaldo","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ceccardi, G., di Cola, F.S., Di Cesare, M., Liberini, P., Magoni, M., Perani, C., Gasparotti, R., Rao, R., and Padovani, A. (2022). Post COVID-19 vaccination headache: A clinical and epidemiological evaluation. Front. Pain Res., 3.","DOI":"10.3389\/fpain.2022.994140"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/03331024211042390","article-title":"The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic","volume":"42","author":"Ekizoglu","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1177\/03331024221099231","article-title":"Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports","volume":"42","author":"Baykan","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40122-021-00296-3","article-title":"Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study","volume":"10","author":"Heinze","year":"2021","journal-title":"Pain Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Jameie, M., Togha, M., Looha, M.A., Jafari, E., Panah, M.Y., Hemmati, N., and Nasergivehchi, S. (2023). Characteristics of headaches attributed to SARS-CoV-2 vaccination and factors associated with its frequency and prolongation: A cross-sectional cohort study. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1214501"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/03331024211038654","article-title":"Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study","volume":"42","author":"Sekiguchi","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s10194-023-01665-3","article-title":"COVID-19 vaccination-related headache showed two different clusters in the long-term course: A prospective multicenter follow-up study (COVA-Head Study)","volume":"24","author":"Atalar","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"fcab169","DOI":"10.1093\/braincomms\/fcab169","article-title":"Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: A multicentre observational cohort study","volume":"3","author":"Heinze","year":"2021","journal-title":"Brain Commun."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/head.14458","article-title":"Post-vaccination headache reporting: Trends according to the Vaccine Adverse Events Reporting System","volume":"63","author":"Cocores","year":"2023","journal-title":"Headache J. Head Face Pain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s11916-022-01094-y","article-title":"Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting","volume":"26","author":"Garces","year":"2022","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00482-022-00687-1","article-title":"Headache associated with COVID-19 vaccination: How to classify?","volume":"37","author":"Straube","year":"2023","journal-title":"Schmerz"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13005-023-00363-4","article-title":"Headache following vaccination against COVID-19 among healthcare workers with a history of COVID-19 infection: A cross-sectional study in Iran with a meta-analytic review of the literature","volume":"19","author":"Nasergivehchi","year":"2023","journal-title":"Head Face Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Martelletti, P. (2023). COVID-19 and SARS-CoV-2 Vaccines: A Cameo Role for Headache. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20053914"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.advms.2023.05.003","article-title":"The development of DNA vaccines against SARS-CoV-2","volume":"68","author":"Khalid","year":"2023","journal-title":"Adv. Med Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-022-01247-x","article-title":"Neurological Complications Following COVID-19 Vaccination","volume":"23","author":"Chatterjee","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/znc-2022-0092","article-title":"Covid-19 vaccines and neurological complications: A systematic review","volume":"78","author":"Allahyari","year":"2023","journal-title":"Z. Naturforschung Sect. C J. Biosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103336","DOI":"10.1016\/j.drudis.2022.08.004","article-title":"The current status of COVID-19 vaccines. A scoping review","volume":"27","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Rabail, R., Ahmed, W., Ilyas, M., Rajoka, M.S.R., Hassoun, A., Khalid, A.R., Khan, M.R., and Aadil, R.M. (2022). The Side Effects and Adverse Clinical Cases Reported after COVID-19 Immunization. Vaccines, 10.","DOI":"10.3390\/vaccines10040488"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s10072-022-05898-z","article-title":"SARS-CoV-2 vaccine-related neurological complications","volume":"43","author":"Oonk","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40264-023-01281-9","article-title":"Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose","volume":"46","author":"Raethke","year":"2023","journal-title":"Drug Saf."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1080\/15321819.2020.1865400","article-title":"Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article","volume":"41","author":"Anwar","year":"2020","journal-title":"J. Immunoass. Immunochem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S1473-3099(20)30709-X","article-title":"The arrival of Sputnik V","volume":"20","author":"Balakrishnan","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Canedo-Marroqu\u00edn, G., Saavedra, F., Andrade, C.A., Berrios, R.V., Rodr\u00edguez-Guilarte, L., Opazo, M.C., Riedel, C.A., and Kalergis, A.M. (2020). SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.569760"},{"key":"ref_54","first-page":"1","article-title":"The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem","volume":"35","author":"Conti","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"ref_57","unstructured":"European Medicines Agency (2023, August 29). COVID-19 Vaccine AstraZeneca. Assessment Report. Procedure No. EMEA\/H\/C\/005675\/0000. 2021; EMA\/94907\/2021: 1\u2013181. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf."},{"key":"ref_58","unstructured":"FDA Briefing Document (2023, August 29). Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020, Available online: https:\/\/www.fda.gov\/media\/144245\/download."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","article-title":"Sputnik V COVID-19 vaccine candidate appears safe and effective","volume":"397","author":"Jones","year":"2021","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.3346\/jkms.2021.36.e107","article-title":"Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: A Single Center Experience","volume":"36","author":"Kim","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1\u20132a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_72","unstructured":"World Health Organization (2023, August 29). The COVID-19 Candidate Vaccine Landscape. Available online: https:\/\/www.who.int\/teams\/blueprint\/covid-19\/covid-19-vaccine-tracker-and-landscape."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","article-title":"A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41232-021-00165-8","article-title":"Neurological pathogenesis of SARS-CoV-2 (COVID-19): From virological features to clinical symptoms","volume":"41","author":"Kase","year":"2021","journal-title":"Inflamm. Regen."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","article-title":"Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19","volume":"24","author":"Meinhardt","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajem.2021.03.040","article-title":"Cerebral venous thrombosis: Diagnosis and management in the emergency department setting","volume":"47","author":"Spadaro","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_81","unstructured":"World Health Organization (2023, August 29). Guidance for Clinical Case Management of Thrombosis with Thrombocytopenia Syndrome (TTS) Following Vaccination to Prevent Coronavirus Disease (COVID-19. Interim Guidance). 19 July 2021. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240061989."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1468-2982.2006.01093.x","article-title":"Headache in United States emergency departments: Demographics, work-up and frequency of pathological diagnoses","volume":"26","author":"Goldstein","year":"2006","journal-title":"Cephalalgia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/head.13281","article-title":"The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies","volume":"58","author":"Burch","year":"2018","journal-title":"Headache J. Head Face Pain"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1212\/WNL.0000000000006697","article-title":"Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list","volume":"92","author":"Do","year":"2019","journal-title":"Neurology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1177\/0333102420965140","article-title":"Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study","volume":"40","author":"Magdy","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2020-5-1","article-title":"Neurological features of COVID-19 and their treatment: A review","volume":"9","author":"Orsucci","year":"2020","journal-title":"Drugs Context"},{"key":"ref_88","first-page":"252","article-title":"SARS-CoV-2: Previous coronaviruses, immune response, and development of vaccines","volume":"77","author":"Bonifaz","year":"2020","journal-title":"Bol. Med. Hosp. Infant. Mex."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jsps.2020.08.024","article-title":"Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective","volume":"28","author":"Alnefaie","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Schlickeiser, S., Schwarz, T., Steiner, S., Wittke, K., Al Besher, N., Meyer, O., Kalus, U., Pru\u00df, A., Kurth, F., and Zoller, T. (2020). Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.628971"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Steiner, S., Sotzny, F., Bauer, S., Na, I.-K., Schmueck-Henneresse, M., Corman, V.M., Schwarz, T., Drosten, C., Wendering, D.J., and Behrends, U. (2020). HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.607918"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.chom.2024.11.007","article-title":"Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19","volume":"32","author":"Rong","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3331024231198792","DOI":"10.1177\/03331024231198792","article-title":"Effect of COVID vaccination on monthly migraine days: A longitudinal cohort study","volume":"43","author":"Bloemhof","year":"2023","journal-title":"Cephalalgia"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Balzanelli, M.G., Distratis, P., Lazzaro, R., Pham, V.H., Tran, T.C., Dipalma, G., Bianco, A., Serlenga, E.M., Aityan, S.K., and Pierangeli, V. (2022). Analysis of Gene Single Nucleotide Polymorphisms in COVID-19 Disease Highlighting the Susceptibility and the Severity towards the Infection. Diagnostics, 12.","DOI":"10.3390\/diagnostics12112824"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/2\/113\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:34:24Z","timestamp":1759919664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/2\/113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":94,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["vaccines13020113"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13020113","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}